Source - RNS
RNS Number : 8864M
Immunodiagnostic Systems Hldgs PLC
19 October 2016
 

 

Immunodiagnostic Systems Holdings plc.

19 October 2016

 

Launch of IDS-iSYS Total Testosterone assay - new assay in the IDS fertility portfolio

 

Immunodiagnostic Systems Holdings plc (IDS), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, has launched the IDS-iSYS Total Testosterone assay in the European market. This is a fully automated CLIA assay for use with serum and plasma samples on the IDS-iSYS Automated System.

 

The launch of the IDS-iSYS Total Testosterone assay is the second product released as part of the emerging fertility (steroid hormones) portfolio following the launch of the IDS-iSYS 17-OH Progesterone assay in May 2016. 

The IDS-iSYS Total Testosterone assay quantitatively measures a patient's Testosterone level and offers clinicians an easy, non-invasive way to diagnose and treat disorders involving the male sex hormones (androgens).

The global market for testosterone tests has been valued at around $110 million per year.

 

For further information:

 

Immunodiagnostic Systems Holdings plc                   Tel: +44 (0) 191 519 0660

Patricio Lacalle, Chief Executive Officer

Paul Martin, Group Finance Director

 

Peel Hunt LLP                                                              Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PRLFFWFWAFMSEES

Related Charts

Immunodiagnostic Systems Holdings (IDH)

0.00p (0.00%)
delayed 18:15PM